Rani Therapeutics Holdings, Inc.

3.44 USD
+0.01 (+0.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rani Therapeutics Holdings, Inc. stock is down -0.29% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January. 100% of analysts rate it a buy.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly. RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis, RT-102, a parathyroid hormone that is in preclinical studies for osteoporosis.